Warning: The NCBI web site requires JavaScript to function. more...
Ivermectin: does P-glycoprotein play a role in neurotoxicity?
Edwards G.
Filaria J. 2003 Oct 24;2 Suppl 1:S8.
Related citations
Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene.
Mealey KL, Bentjen SA, Gay JM, Cantor GH.
Pharmacogenetics. 2001 Nov;11(8):727-33.
The ABCB1-1Delta mutation is not responsible for subchronic neurotoxicity seen in dogs of non-collie breeds following macrocyclic lactone treatment for generalized demodicosis.
Bissonnette S, Paradis M, Daneau I, Silversides DW.
Vet Dermatol. 2009 Feb;20(1):60-6.
Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J, Gavrilova O, Petzinger E.
J Vet Pharmacol Ther. 2009 Feb;32(1):87-96.
The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases.
Thuerauf N, Fromm MF.
Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):281-6. Review.
MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin.
Roulet A, Puel O, Gesta S, Lepage JF, Drag M, Soll M, Alvinerie M, Pineau T.
Eur J Pharmacol. 2003 Jan 24;460(2-3):85-91.
Evaluation of the role of P-glycoprotein in ivermectin uptake by primary cultures of bovine brain microvessel endothelial cells.
Rose JM, Peckham SL, Scism JL, Audus KL.
Neurochem Res. 1998 Feb;23(2):203-9.
P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity.
Lankas GR, Cartwright ME, Umbenhauer D.
Toxicol Appl Pharmacol. 1997 Apr;143(2):357-65.
Changes in the use profile of Mectizan: 1987-1997.
Brown KR.
Ann Trop Med Parasitol. 1998 Apr;92 Suppl 1:S61-4. Review.
Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans.
Macdonald N, Gledhill A.
Arch Toxicol. 2007 Aug;81(8):553-63. Epub 2007 Mar 13. Review.
Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
Mackenzie CD, Geary TG, Gerlach JA.
Filaria J. 2003 Oct 24;2 Suppl 1:S5.
Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice.
Marques-Santos LF, Bernardo RR, de Paula EF, Rumjanek VM.
Pharmacol Toxicol. 1999 Mar;84(3):125-9.
Treatment of MDR1 mutant dogs with macrocyclic lactones.
Geyer J, Janko C.
Curr Pharm Biotechnol. 2011 Oct 31. [Epub ahead of print]
Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas.
Filaria J. 2003 Oct 24;2 Suppl 1:S2.
Assessing neuroprotective P-glycoprotein activity at the blood-brain barrier in killifish (Fundulus heteroclitus) using behavioural profiles.
Bard SM, Gadbois S.
Mar Environ Res. 2007 Dec;64(5):679-82. Epub 2007 Jul 19.
Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity.
Mealey KL, Northrup NC, Bentjen SA.
J Am Vet Med Assoc. 2003 Nov 15;223(10):1453-5, 1434.
Therapeutic implications of the MDR-1 gene.
Mealey KL.
J Vet Pharmacol Ther. 2004 Oct;27(5):257-64. Review.
Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR.
Ott M, Fricker G, Bauer B.
J Pharmacol Exp Ther. 2009 Apr;329(1):141-9. Epub 2009 Jan 15.
P-Glycoprotein, a gatekeeper in the blood-brain barrier.
Schinkel AH.
Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):179-194.
The Mectizan Donation Program (MDP).
Thylefors B.
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:39-44.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on